Cognitive Research Corporation (CRC) announces the acquisition of Jupiter Point Pharma Consulting, LLC. Since 2009, Jupiter Point has provided statistical input to drug development programs, including design, analysis, and interpretation of clinical trials in support of regulatory submission for a wide variety of programs, and for emerging companies and large pharma across the globe. In that time, Jupiter Point has also extensively represented these companies in regulatory settings and has provided pivotal analyses on the probability of technical and regulatory success for investment organizations.
With this acquisition, Jeff Finman has been appointed SVP, Chief of Biostatistics at CRC. Dr. Finman previously served as Founder and Principle of Jupiter Point Pharma Consulting and brings 37 years of drug development experience providing statistical expertise to the pharmaceutical and biotech industries.
C.G. (Chip) Gillooly, Chief Executive Officer of CRC commented “Jeff has been a vital part of our solution set to clients for quite a while now and it only made sense to solidify our partnership with this acquisition. I look forward to Jeff and his team providing valuable insights to our clients as they work to advance new drugs and therapies to address a wide range of mental health needs.
About Cognitive Research Corporation:
CRC’s mission is to support innovative companies developing new medicines and therapies to improve mental health. As a leading neuroscience clinical research organization (CRO) and technology company, CRC works with sponsors, specialized clinical trial sites, and CNS experts to bring new drugs through rigorous testing and ultimately to market. For more information visit us here.